X
XyloCor Therapeutics
Focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease
About XyloCor Therapeutics
XyloCor Therapeutics is a biotechnology company dedicated to enhancing the lives of individuals suffering from cardiovascular disease through the advancement of gene therapy. The company specializes in developing gene therapy treatments specifically for advanced coronary artery disease, a severe condition that affects the heart's blood vessels. XyloCor's innovative approach is rooted in proprietary gene therapy technologies developed in collaboration with Weill Cornell Medical College.
The primary clients of XyloCor are patients with advanced coronary artery disease, a demographic that often has limited treatment options. The company operates within the biotechnology and healthcare markets, focusing on cutting-edge medical research and development.
XyloCor's business model revolves around the research, development, and eventual commercialization of gene therapy products. Revenue is generated through a combination of research grants, partnerships with medical institutions, and future sales of their gene therapy treatments once they receive regulatory approval.
By addressing a critical unmet need in cardiovascular health, XyloCor aims to provide a transformative impact on patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 80.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2025 | $68M | $270M | Fountain Healthcare Partners · Jeito Capital · EQT Life Sciences · Lumira Ventures | ↗ |
| SERIES AOther financing | Mar 2021 | $23M | $90M | Longwood Fund · Lumira Ventures · Fountain Healthcare Partners · EQT Life Sciences | — |
Growth signals
Latest recorded traffic for XyloCor Therapeutics is 2K monthly website visits, up 81.8% over the last three months. XyloCor Therapeutics's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
XyloCor Therapeutics in the Upper Merion Township ecosystem
The XyloCor Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
EQT Life Sciences
Sofinnova Investments
Fountain Healthcare Partners
Longwood Fund
Lumira Ventures
Jeito Capital
Other known investors2 additional known investors
Cornell Tech
Cornell University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about XyloCor Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See XyloCor Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







